| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/31/2001 | WO2001037861A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 05/31/2001 | WO2001037860A1 Method of inducing immune tolerance |
| 05/31/2001 | WO2001037859A2 Pharmaceutical compositions containing compounds which increase or decrease tmtnf levels |
| 05/31/2001 | WO2001037858A1 Implantable substrates for healing connective tissue |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001037856A1 Urotensin-ii cyclic analogs |
| 05/31/2001 | WO2001037855A2 Temperature dependent neuronal rescue |
| 05/31/2001 | WO2001037854A1 Method for treatment and prevention of physiological shock |
| 05/31/2001 | WO2001037853A2 Methods and agents for the inhibition of smooth muscle cell proliferation |
| 05/31/2001 | WO2001037852A2 Methods of inhibiting atrophy or promoting hypertrophy |
| 05/31/2001 | WO2001037850A2 Use of a milk protein hydrolysate in the treatment of diabetes |
| 05/31/2001 | WO2001037847A2 Nontoxic vernix compositions and method of producing |
| 05/31/2001 | WO2001037846A1 Method and composition for the treatment of adenoviral ocular infections |
| 05/31/2001 | WO2001037821A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | WO2001037809A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037801A1 Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| 05/31/2001 | WO2001037788A1 Topical skin composition |
| 05/31/2001 | WO2001037784A2 Method for preventing irinotecan induced diarrhea |
| 05/31/2001 | WO2001037780A2 Urotensin-ii analogs |
| 05/31/2001 | WO2001037779A2 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 05/31/2001 | WO2001009186A3 Therapeutic compounds comprised of anti-fc receptor binding agents |
| 05/31/2001 | WO2001004139A3 Human axor29 receptor |
| 05/31/2001 | WO2001002571A3 An interleukin-1 receptor antagonist and uses thereof |
| 05/31/2001 | WO2000075172A3 Factor viia inhibitors |
| 05/31/2001 | WO2000072880A3 Prevention and treatment of amyloidogenic disease |
| 05/31/2001 | WO2000071555A3 509rr |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000066708A3 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000056350A3 Methods of use of beta 1-integrin inhibitors |
| 05/31/2001 | WO2000055345A3 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 05/31/2001 | WO2000053630A3 COMPOUNDS THAT DISRUPT MAMMALIAN Rad51 ACTIVITY |
| 05/31/2001 | WO2000045853A3 Treatment of tumors with genetically engineered herpes virus |
| 05/31/2001 | WO2000042165A3 Bone marrow-specific protein |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/31/2001 | WO2000032772A3 Erythropoietic compounds |
| 05/31/2001 | WO2000010507A3 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 05/31/2001 | WO2000000617A3 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | WO1999060124A3 Differentiation-associated sequences and methods of use therefor |
| 05/31/2001 | WO1999054479A3 INHIBITION OF ALKYL HYDROPEROXIDE REDUCTASE, SUBUNIT C (AhpC) TO IMPART SUSCEPTIBILITY TO ANTIMICROBIAL REACTIVE NITROGEN INTERMEDIATES |
| 05/31/2001 | WO1999028341A9 Maintenance of smooth muscle integrity by morphogenic proteins |
| 05/31/2001 | WO1999024553A9 X-ray crystal comprising hiv-1 gp120 |
| 05/31/2001 | WO1999006554B1 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| 05/31/2001 | US20010002419 Homogeneous preparation of protein, e.g. leptin, modified at the N-terminal only by an anhydride, e.g. succinic anhydride, ethylenediaminetetraacetic dianhydride; improved solubility; no inflammation at injection sites |
| 05/31/2001 | US20010002394 Use of a polypeptide containing specific amino acid sequence or analogue or derivatives as a drug for the treatment of diabetes together with an oral hypoglycemic agent |
| 05/31/2001 | US20010002393 Administering to a patient suffering from leiomyoma (fibroid)of uterus an effective dose of an agent which specifically inhibit metalloproteinase selected from stromelysin-2, stromelysin-3 and matrilysin |
| 05/31/2001 | US20010002392 Administrated an effective amount of cartilage oligomeric matrix protein(COMP) to prevent or treat the rheumatoid arthritic condition of a mamal |
| 05/31/2001 | US20010002391 Administering to the mammal for ischmeic treatment an effective amount of an necrosis factor(NF)- kappa B activation inhibitor selected from the group consisting of proteasome inhibitor, ubiquitin pathwaty inhibitors |
| 05/31/2001 | US20010002263 Complex of human growth hormone and zinc and use |
| 05/31/2001 | US20010002255 Medicaments |
| 05/31/2001 | DE19957342A1 Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine |
| 05/31/2001 | DE19954444A1 Verfahren zum Schutz von Säugetierzellen mittels überexprimierter G-2/M-Zellzykluskoppler A method of protecting mammalian cells by means of overexpressed G-2 / M-Zellzykluskoppler |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2429394A1 Method of inducing immune tolerance |
| 05/31/2001 | CA2422429A1 A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392490A1 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| 05/31/2001 | CA2392472A1 Use of disease-associated gene |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392355A1 Oxidized apolipoproteins and methods of use |
| 05/31/2001 | CA2392351A1 Novel transcription factor and dna thereof |
| 05/31/2001 | CA2392217A1 Methods of inhibiting atrophy or promoting hypertrophy |
| 05/31/2001 | CA2392175A1 A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance |
| 05/31/2001 | CA2392019A1 Method of forming a peptide-receptor complex with zsig33 |
| 05/31/2001 | CA2391986A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 05/31/2001 | CA2391943A1 Cell permeable peptides for inhibition of inflammatory reactions and methods of use |
| 05/31/2001 | CA2391922A1 Excipient system that contains coating substances with enzymatically removable side-groups |
| 05/31/2001 | CA2391386A1 Peptides having antiangiogenic activity |
| 05/31/2001 | CA2390802A1 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 05/31/2001 | CA2390767A1 Nontoxic vernix compositions and method of producing |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2390344A1 85kda neisserial antigen |
| 05/31/2001 | CA2386893A1 N-alkylated peptides having antiangiogenic activity |
| 05/31/2001 | CA2370322A1 Novel peptide dimers as agonists of the erythropoietin (epo) receptor, and associated methods of synthesis and use |
| 05/31/2001 | CA2366230A1 Primary nucleotide sequence of the shrimp white spot bacilliform virus (wsbv), discovery systems containing this sequence and detection kits and antiviral targets for detection and controlling shrimp virus outbreak and spread |
| 05/30/2001 | EP1103623A1 Human mucin core protein: nucleic acid probes, peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods |
| 05/30/2001 | EP1103608A1 CIDE-like protein, its isolation and uses |
| 05/30/2001 | EP1103607A1 Enhancement of tmTNF levels for the sensitisation of tumours to sTNF and/or cytostatic drugs |
| 05/30/2001 | EP1103564A1 Cancer antigens based on tumor suppressor gene wt1 product |
| 05/30/2001 | EP1103562A1 Novel g-protein coupled receptor protein and dna thereof |
| 05/30/2001 | EP1103561A1 Hla-a2 restraint tumor antigen peptide originating in sart-1 |
| 05/30/2001 | EP1103560A1 Novel thiazolidine derivatives |
| 05/30/2001 | EP1103272A2 Modulation of TGF-beta by proteolytic enzymes |
| 05/30/2001 | EP1103270A1 Method for treating endotoxic shock and inflammatory and autoimmune diseases in mammals |
| 05/30/2001 | EP1103269A1 Preparations for the administration of hepatocyte growth factor |
| 05/30/2001 | EP1103268A1 Use of staphylococcal enterotoxins or related compounds for cancer treatment by infusion |
| 05/30/2001 | EP1103267A1 Botulinum toxins for treating various disorders and associated pain |
| 05/30/2001 | EP1102862A1 Antisense oligonucleotides targeted to il-15 |
| 05/30/2001 | EP1102853A1 N-acetylglycosaminyltransferase genes |
| 05/30/2001 | EP1102850A1 Regions of papilloma virus e1 helicase involved in e1 oligomerization |
| 05/30/2001 | EP1102848A2 Molecules designated ldcam |
| 05/30/2001 | EP1102847A2 Novel tension-dependent potassium channel and the use thereof in the development of new therapeutic agents |
| 05/30/2001 | EP1102845A1 Calcium/calmodulin dependent kinase and an alternative splice product thereof |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102790A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 05/30/2001 | EP1102789A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |